Samsung Biologics to buy US drug production facility from GSK for $280 million

Samsung Biologics is acquiring its first U.S. drug production facility from GSK for $280 million to meet long-term U.S. market demand. The South Korean contract drug manufacturer plans to expand the Maryland site's capacity and upgrade its technology. The deal is expected to close around the end of the first quarter of 2026.